FIELD: biotechnology.
SUBSTANCE: invention relates to biotechnology, specifically to recombinant molecules of transforming growth factor beta (TGFβR2) and can be used in medicine for treating a tumour associated with EGFR.
EFFECT: invention provides obtaining a TGFβR2 molecule with a truncated extracellular domain, which, when combined with an antibody targeting a cancer cell, is more resistant to protease cleavage compared to the natural form of the TGFβR2 molecule.
12 cl, 35 dwg, 25 tbl, 8 ex
| Title | Year | Author | Number |
|---|---|---|---|
| BISPECIFIC FUSION PROTEIN AND ITS USE | 2021 |
|
RU2801528C2 |
| RECOMBINANT PROTEINS WITH CCN DOMAINS AND FUSION PROTEINS | 2020 |
|
RU2825102C2 |
| FUSED PROTEINS WITH ALBUMIN-BINDING DOMAINS | 2018 |
|
RU2786444C2 |
| FUSED PROTEIN CONSTRUCTS FOR COMPLEMENT-RELATED DISEASE | 2019 |
|
RU2824402C2 |
| FUNCTION PROTEIN AND ITS USE | 2019 |
|
RU2800923C2 |
| POLYVALENT AND POLYSPECIFIC GITR-BINDING FUSED PROTEINS | 2016 |
|
RU2753439C2 |
| DISPLAY OF AN INTEGRAL MEMBRANE PROTEIN ON EXTRACELLULAR ENVELOPED POXVIRUS VIRIONS | 2017 |
|
RU2759846C2 |
| FUSED MOLECULES DERIVED FROM CHOLIX-TOXIN FOR ORAL DELIVERY OF BIOLOGICALLY ACTIVE LOADS | 2015 |
|
RU2723178C2 |
| POLYVALENT AND POLYSPECIFIC OX40-BINDING FUSED PROTEINS | 2017 |
|
RU2773052C2 |
| FUSED POLYPEPTIDE WITH ANTI-CANCER ACTIVITY | 2016 |
|
RU2754466C2 |
